Skip Navigation

Steven DuBois, MD, MS


Pediatric Hematology/Oncology

Make an Appointment
Watch Video

Physician

  • Director, Experimental Therapeutics
  • Senior Physician
  • Associate Professor of Pediatrics, Harvard Medical School

Centers/Programs

Clinical Interests

  • Ewing sarcoma
  • Neuroblastoma
  • Novel agents
  • Other pediatric solid tumors
  • Phase 1 clinical trials

Contact Information

  • Appointments888-733-4662 (new)
    617-632-3270 (established)
  • Office Phone Number617-632-5460
  • Fax617-632-5710

Bio

Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents. His clinical practice focuses on providing outstanding team-based care for children and young adults with solid cancers. He is also a member of the American Pediatric Society.

Board Certification:

  • Pediatric Hematology/Oncology, 2009

Fellowship:

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency:

  • University of California, San Francisco School of Medicine, Pediatrics

Medical School:

  • University of California, San Francisco School of Medicine

Recent Awards:

  • Dana-Farber Cancer Institute Clinical Innovation Award, 2020

Research

Dr. DuBois is director of experimental therapeutics at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He is a pediatric oncologist with an active clinical and translational research program focused on patients with advanced neuroblastoma and Ewing sarcoma. He conducts phase 1 and 2 clinical trials of novel targeted agents.

Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE. Eur J Cancer. 2021 Mar; 146:115-124.
View in: PubMed

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. Cancer Chemother Pharmacol. 2021 Jan 28.
View in: PubMed

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Med. 2021 Feb; 10(3):843-856.
View in: PubMed

A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. Pediatr Blood Cancer. 2021 Apr; 68(4):e28780.
View in: PubMed

Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discov. 2021 Mar; 11(3):545-559.
View in: PubMed

Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis. Pediatr Blood Cancer. 2021 Mar; 68(3):e28834.
View in: PubMed

Stereotactic Body Radiation Therapy for Metastatic and Recurrent Solid Tumors in Children and Young Adults. Int J Radiat Oncol Biol Phys. 2021 Apr 01; 109(5):1396-1405.
View in: PubMed

Role of bone marrow biopsy for staging new patients with Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2021 Feb; 68(2):e28807.
View in: PubMed

Advances and Challenges in Pediatric and Childhood Cancers. Cancer Cell. 2020 10 12; 38(4):429-432.
View in: PubMed

Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. J Pediatr Hematol Oncol. 2020 10; 42(7):e647-e654.
View in: PubMed

The Impact of COVID-19 on Clinical Trial Execution at the Dana-Farber Cancer Institute. J Natl Cancer Inst. 2020 Sep 22.
View in: PubMed

Landscape of phase 1 clinical trials for minors with cancer in the United States. Pediatr Blood Cancer. 2020 11; 67(11):e28694.
View in: PubMed

The RACE to accelerate drug development for children with cancer. Lancet Child Adolesc Health. 2020 10; 4(10):714-716.
View in: PubMed

Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center. Cancer Med. 2020 09; 9(18):6658-6666.
View in: PubMed

Trends in conditional survival and predictors of late death in neuroblastoma. Pediatr Blood Cancer. 2020 10; 67(10):e28329.
View in: PubMed

The use of interval-compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatr Blood Cancer. 2020 10; 67(10):e28559.
View in: PubMed

Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. Eur J Cancer. 2020 09; 136:52-68.
View in: PubMed

Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors. Cancer Chemother Pharmacol. 2020 08; 86(2):181-192.
View in: PubMed

NUT Carcinoma Without Upfront Surgical Resection: A Case Report. J Pediatr Hematol Oncol. 2020 Jun 16.
View in: PubMed

Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752.
View in: PubMed

Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. Eur J Cancer. 2020 07; 133:112-119.
View in: PubMed

How to address challenges and opportunities in pediatric cancer drug development? Expert Opin Drug Discov. 2020 08; 15(8):869-872.
View in: PubMed

Sponsorship of oncology clinical trials in the United States according to age of eligibility. Cancer Med. 2020 07; 9(13):4495-4500.
View in: PubMed

DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol. 2020 10; 33(10):1910-1921.
View in: PubMed

The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers. Paediatr Drugs. 2020 Apr; 22(2):189-197.
View in: PubMed

Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clin Cancer Res. 2020 06 15; 26(12):2882-2890.
View in: PubMed

Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers. J Natl Cancer Inst. 2020 03 01; 112(3):224-228.
View in: PubMed

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 04; 21(4):531-540.
View in: PubMed

New approaches to therapeutic drug development for childhood cancers. Curr Opin Pediatr. 2020 02; 32(1):35-40.
View in: PubMed

Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. AAPS J. 2020 01 23; 22(2):31.
View in: PubMed

Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 05 15; 26(10):2297-2307.
View in: PubMed

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 01; 21(1):121-133.
View in: PubMed

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
View in: PubMed

A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707.
View in: PubMed

Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma. J Natl Cancer Inst. 2019 11 01; 111(11):1192-1201.
View in: PubMed

Author Correction: Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. Sci Rep. 2019 Oct 15; 9(1):15009.
View in: PubMed

Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019 11; 66(11):e27938.
View in: PubMed

Clinical Impact of Tumor Mutational Burden in Neuroblastoma. J Natl Cancer Inst. 2019 07 01; 111(7):695-699.
View in: PubMed

Reprogramming Escherichia coli for the production of prenylated indole diketopiperazine alkaloids. Sci Rep. 2019 06 25; 9(1):9208.
View in: PubMed

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 08; 66(8):e27819.
View in: PubMed

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Res. 2019; 8.
View in: PubMed

Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 05; 112:66-79.
View in: PubMed

Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2019 Apr; 120(8):869.
View in: PubMed

Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors. Am J Surg Pathol. 2019 04; 43(4):435-445.
View in: PubMed

Timing of first-in-child trials of FDA-approved oncology drugs. Eur J Cancer. 2019 05; 112:49-56.
View in: PubMed

Ushering in the next generation of precision trials for pediatric cancer. Science. 2019 Mar 15; 363(6432):1175-1181.
View in: PubMed

Winning the RACE: Expanding pediatric cancer drug approvals. Pediatr Blood Cancer. 2019 08; 66(8):e27705.
View in: PubMed

Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors. JCO Precis Oncol. 2019; 3.
View in: PubMed

Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatr Blood Cancer. 2019 05; 66(5):e27595.
View in: PubMed

Risk stratification by somatic mutation burden in Ewing sarcoma. Cancer. 2019 04 15; 125(8):1357-1364.
View in: PubMed

Neuroblastoma and Histone Demethylation. N Engl J Med. 2018 10 11; 379(15):1476-1477.
View in: PubMed

Genome-Informed Targeted Therapy for Osteosarcoma. Cancer Discov. 2019 01; 9(1):46-63.
View in: PubMed

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas. Cancer. 2018 11 01; 124(21):4241-4247.
View in: PubMed

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. Br J Cancer. 2018 08; 119(5):615-621.
View in: PubMed

Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2018 12 15; 24(24):6142-6149.
View in: PubMed

Comparison of Epidemiology, Clinical Features, and Outcomes of Patients with Reported Ewing Sarcoma and PNET over 40 Years Justifies Current WHO Classification and Treatment Approaches. Sarcoma. 2018; 2018:1712964.
View in: PubMed

Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. Pediatr Blood Cancer. 2018 09; 65(9):e27251.
View in: PubMed

Dual HDAC and PI3K Inhibition Abrogates NF?B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Res. 2018 07 15; 78(14):4007-4021.
View in: PubMed

Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. Oncotarget. 2018 Apr 06; 9(26):18607-18626.
View in: PubMed

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatr Blood Cancer. 2018 07; 65(7):e27023.
View in: PubMed

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2018 05; 19(5):705-714.
View in: PubMed

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739.
View in: PubMed

Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018 03; 31(3):463-473.
View in: PubMed

Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol. 2017 May; 34(4):231-237.
View in: PubMed

Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol. 2017 May; 34(4):187-198.
View in: PubMed

Identification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group. Int J Radiat Oncol Biol Phys. 2017 12 01; 99(5):1286-1294.
View in: PubMed

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 2017 Nov 01; 123(21):4224-4235.
View in: PubMed

Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After 131I- Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):468-475.
View in: PubMed

Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11).
View in: PubMed

A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017 May 15; 23(10):2433-2441.
View in: PubMed

MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 Nov; 64(11).
View in: PubMed

Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017 Apr 04; 8(14):23851-23861.
View in: PubMed

Comparison of Clinical Features and Outcomes in Patients With Bilateral Versus Unilateral Adrenal Neuroblastoma. J Pediatr Hematol Oncol. 2017 03; 39(2):108-113.
View in: PubMed

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
View in: PubMed

Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma. Sarcoma. 2017; 2017:8758623.
View in: PubMed

A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors. Oncotarget. 2016 Dec 20; 7(51):84736-84747.
View in: PubMed

Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277.
View in: PubMed

Assessment of Chemotherapy Response in Ewing Sarcoma: Response Radiology. 2016 11; 281(2):647-649.
View in: PubMed

Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016 12 20; 34(36):4381-4389.
View in: PubMed

Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors. Clin Cancer Res. 2017 Apr 01; 23(7):1852-1861.
View in: PubMed

Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine. Eur J Cancer. 2016 10; 66:144-52.
View in: PubMed

Transcript Analysis for Internal Biodosimetry Using Peripheral Blood from Neuroblastoma Patients Treated with (131)I-mIBG, a Targeted Radionuclide. Radiat Res. 2016 09; 186(3):235-44.
View in: PubMed

Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatr Blood Cancer. 2016 11; 63(11):1974-82.
View in: PubMed

Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy? Pediatr Blood Cancer. 2016 10; 63(10):1868.
View in: PubMed

Erratum to: Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Jul; 43(7):1396.
View in: PubMed

Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2016 10; 63(10):1771-9.
View in: PubMed

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. Clin Sarcoma Res. 2016; 6:9.
View in: PubMed

Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours. Eur J Cancer. 2016 07; 62:9-17.
View in: PubMed

Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615.
View in: PubMed

Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genet. 2016 05; 209(5):182-94.
View in: PubMed

Clinical Characteristics and Outcomes of Pediatric Patients with Desmoplastic Small Round Cell Tumor. Rare Tumors. 2016 Mar 21; 8(1):6145.
View in: PubMed

Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. Radiology. 2016 09; 280(3):905-15.
View in: PubMed

A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Aug 15; 22(16):4014-22.
View in: PubMed

Conditional Survival and Predictors of Late Death in Patients With Ewing Sarcoma. Pediatr Blood Cancer. 2016 Jun; 63(6):1091-5.
View in: PubMed

Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016 Apr 20; 34(12):1368-75.
View in: PubMed

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clin Cancer Res. 2016 07 15; 22(14):3643-50.
View in: PubMed

Assessment of extent of surgical resection of primary high-grade osteosarcoma by treating institutions: A report from the Children's Oncology Group. J Surg Oncol. 2016 Mar; 113(4):351-4.
View in: PubMed

Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project. Cancer. 2016 Mar 15; 122(6):935-45.
View in: PubMed

Extended Sedation With Continuous Midazolam or Dexmedetomidine Infusion for Young Children Receiving 131 I-MIBG Radiopharmaceutical Therapy for Advanced Neuroblastoma. Pediatr Blood Cancer. 2016 Mar; 63(3):471-8.
View in: PubMed

Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania. Pediatr Blood Cancer. 2016 Mar; 63(3):458-64.
View in: PubMed

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2016 Mar; 63(3):436-42.
View in: PubMed

Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016 Jan 01; 122(1):116-23.
View in: PubMed

Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group. Eur J Nucl Med Mol Imaging. 2016 Mar; 43(3):474-481.
View in: PubMed

Identification of Discrete Prognostic Groups in Ewing Sarcoma. Pediatr Blood Cancer. 2016 Jan; 63(1):47-53.
View in: PubMed

Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG). Eur J Cancer. 2015 Nov; 51(16):2465-72.
View in: PubMed

Clinical features and outcomes of infants with Ewing sarcoma under 12 months of age. Pediatr Blood Cancer. 2015 Nov; 62(11):1947-51.
View in: PubMed

Patient-specific dosimetry using pretherapy [¹²4I]m-iodobenzylguanidine ([¹²4I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015 Apr; 17(2):284-94.
View in: PubMed

Second malignant neoplasms among children, adolescents and young adults with Wilms tumor. Pediatr Blood Cancer. 2015 Jul; 62(7):1259-64.
View in: PubMed

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15; 21(12):2715-21.
View in: PubMed

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma. Br J Cancer. 2015 Feb 17; 112(4):644-9.
View in: PubMed

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4.
View in: PubMed

Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51.
View in: PubMed

Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children's Oncology Group. Cancer. 2015 Feb 01; 121(3):467-75.
View in: PubMed

Clinical Features and Outcomes Differ between Skeletal and Extraskeletal Osteosarcoma. Sarcoma. 2014; 2014:902620.
View in: PubMed

Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma. Appl Immunohistochem Mol Morphol. 2014 Sep; 22(8):593-9.
View in: PubMed

Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014 Oct 01; 32(28):3169-76.
View in: PubMed

Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer. 2014 Dec 15; 120(24):3987-93.
View in: PubMed

Pediatric cancer type predicts infection rate, need for critical care intervention, and mortality in the pediatric intensive care unit. Intensive Care Med. 2014 Oct; 40(10):1536-44.
View in: PubMed

Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):839-45.
View in: PubMed

Current treatment and outcome for childhood acute leukemia in Tanzania. Pediatr Blood Cancer. 2013 Dec; 60(12):2047-53.
View in: PubMed

Comparison of Latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer. 2014 Feb; 61(2):233-7.
View in: PubMed

Adverse impact of regional lymph node involvement in osteosarcoma. Eur J Cancer. 2013 Nov; 49(16):3471-6.
View in: PubMed

Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution. Clin Ophthalmol. 2013; 7:981-9.
View in: PubMed

Acute changes in blood pressure in patients with neuroblastoma treated with ¹³¹I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer. 2013 Sep; 60(9):1424-30.
View in: PubMed

131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastoma. Q J Nucl Med Mol Imaging. 2013 Mar; 57(1):53-65.
View in: PubMed

Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosis. J Pediatr Hematol Oncol. 2012 Oct; 34(7):548-51.
View in: PubMed

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma. Pediatr Blood Cancer. 2013 May; 60(5):879-84.
View in: PubMed

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group. Int J Mol Imaging. 2012; 2012:250834.
View in: PubMed

Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosis. Cancer Epidemiol. 2013 Feb; 37(1):29-33.
View in: PubMed

Clinical features and outcomes in patients with secondary Ewing sarcoma. Pediatr Blood Cancer. 2013 Apr; 60(4):611-5.
View in: PubMed

Evaluation of plasma annexin V levels in children and young adults with solid tumors. Int J Biol Markers. 2012 Jul 19; 27(2):e164-6.
View in: PubMed

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012 Jul; 53(7):1155-63.
View in: PubMed

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902.
View in: PubMed

Proteinuria in metastatic pheochromocytoma is associated with an increased risk of Acute Respiratory Distress Syndrome, spontaneously or after therapy with 131I-meta-iodobenzylguanidine (131I-MIBG). Horm Metab Res. 2012 Jun; 44(7):539-42.
View in: PubMed

Rates and appropriateness of antimicrobial prescribing at an academic children's hospital, 2007-2010. Infect Control Hosp Epidemiol. 2012 Apr; 33(4):346-53.
View in: PubMed

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial. Clin Cancer Res. 2012 May 01; 18(9):2679-86.
View in: PubMed

Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvement. Pediatr Blood Cancer. 2012 Oct; 59(4):617-20.
View in: PubMed

Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7.
View in: PubMed

Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcoma. Pediatr Blood Cancer. 2012 Oct; 59(4):611-6.
View in: PubMed

Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. J Clin Oncol. 2011 Nov 20; 29(33):4358-64.
View in: PubMed

Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2012 Jul 15; 59(1):52-6.
View in: PubMed

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22.
View in: PubMed

Dosimetry, toxicity, and response in a phase IIa trial of no-carrier added iobenguane I-131 (nca-MIBG): A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol. 2011 May 20; 29(15_suppl):9512.
View in: PubMed

Surrogate biomarkers of antiangiogenesis in Children's Oncology Group (COG) phase I trials. J Clin Oncol. 2011 May 20; 29(15_suppl):9502.
View in: PubMed

Phase I study of vincristine, irinotecan, and 131I-MIBG for patients with relapsed or refractory neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) study. J Clin Oncol. 2011 May 20; 29(15_suppl):9513.
View in: PubMed

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Lett. 2011 Jul 28; 306(2):223-9.
View in: PubMed

Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49.
View in: PubMed

Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults. Cancer. 2011 Sep 15; 117(18):4286-93.
View in: PubMed

Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcoma. Pediatr Blood Cancer. 2012 Feb; 58(2):181-4.
View in: PubMed

Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011 Jul 01; 117(13):3027-32.
View in: PubMed

Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocation. Cancer Epidemiol Biomarkers Prev. 2011 Mar; 20(3):449-53.
View in: PubMed

Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010 Aug; 55(2):254-9.
View in: PubMed

Osteosarcoma in children 5 years of age or younger at initial diagnosis. Pediatr Blood Cancer. 2010 Aug; 55(2):285-9.
View in: PubMed

p53+/mdm2- atypical lipomatous tumor/well-differentiated liposarcoma in young children: an early expression of Li-Fraumeni syndrome. Pediatr Dev Pathol. 2010 May-Jun; 13(3):218-24.
View in: PubMed

Ethnic and racial differences in patients with Ewing sarcoma. Cancer. 2010 Feb 15; 116(4):983-8.
View in: PubMed

Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010 Feb 01; 116(3):749-57.
View in: PubMed

Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrow. Pediatr Blood Cancer. 2010 Jan; 54(1):13-8.
View in: PubMed

Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):10502.
View in: PubMed

Significance of tumor biology compared to metastatic pattern (INSS 4 versus 4s) and age for prognosis of neuroblastoma less than 18 months of age. J Clin Oncol. 2009 May 20; 27(15_suppl):10010.
View in: PubMed

Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys. 2009 Sep 01; 75(1):177-82.
View in: PubMed

Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. Nat Rev Clin Oncol. 2009 May; 6(5):251-3.
View in: PubMed

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009 Mar; 52(3):324-7.
View in: PubMed

Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer. 2009 Mar; 52(3):387-91.
View in: PubMed

Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008 Dec; 52(4):403-18.
View in: PubMed

Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92.
View in: PubMed

Late recurrence of ewing sarcoma during pregnancy: a report of 2 cases. J Pediatr Hematol Oncol. 2008 Sep; 30(9):716-8.
View in: PubMed

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008 Aug; 35 Suppl 1:S35-48.
View in: PubMed

Early lymphocyte recovery in Ewing sarcoma. J Pediatr Hematol Oncol. 2007 May; 29(5):351-2.
View in: PubMed

Desmoplastic small round cell tumor of the kidney in childhood. Am J Surg Pathol. 2007 Apr; 31(4):576-84.
View in: PubMed

Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007 Mar 01; 109(5):813-9.
View in: PubMed

Combined effects of granulocyte colony stimulating factor and radiation. Clin Nucl Med. 2007 Jan; 32(1):39-41.
View in: PubMed

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004 Jun 15; 22(12):2452-60.
View in: PubMed

Pediatric acute blastic natural killer cell leukemia. Leuk Lymphoma. 2002 Apr; 43(4):901-6.
View in: PubMed

Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999 May-Jun; 21(3):181-9.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top